Dr. Aparna Kalyan, MD

Dr. Kalyan practices at Northwestern Memorial Hospital in Chicago, Illinois, part of Northwestern Memorial HealthCare.

Dr. Kalyan's NPI, 1447482443, was assigned on August 10, 2009. Dr. Kalyan holds Illinois license 036136040.

Dr. Kalyan's primary practice is Northwestern Memorial Hospital, at 251 E Huron St, Chicago, IL 60611 in Cook County. The practice phone is (312) 926-2000.

Dr. Kalyan's primary practice is Northwestern Memorial Hospital in Chicago, Illinois, part of Northwestern Memorial HealthCare. Dr. Kalyan is also affiliated with Northwestern Medicine Central DuPage Hospital. The medical group on file is Northwestern Medical Faculty Foundation. Dmand AI also links Dr. Kalyan to 3 more hospitals, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kalyan practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kalyan's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Kalyan's licenses on file in 3 states: Illinois, Ohio and Pennsylvania.

CMS data shows 71,891 Medicare services from Dr. Kalyan across 39 procedure codes in 2024, for 419 Medicare patients. Medicare paid $1,429,980 for them.

CMS counts 419 Medicare patients who saw Dr. Kalyan in 2024. The largest group is 65 to 74, with 203 patients. 72% of them have high blood pressure, and 68% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kalyan's median patient age at 71, with 52% women.

In 2024, Dr. Kalyan wrote 191 Medicare Part D claims for 55 patients. 74% of them were for generic drugs. CMS names the drug for 81 of them, across 5 drugs with 11 or more claims each, at $68,978 in total drug cost. In 2023, CMS named 117 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Kalyan for performance year 2024, reported through an alternative payment model (APM). Dr. Kalyan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kalyan as offering telehealth.

Dmand AI links 47 papers to Dr. Kalyan, published from 2014 to 2025. 2017 was the busiest year, with 4. The most frequent topics are Liver Neoplasms, Cholangiocarcinoma and Yttrium Radioisotopes. Dr. Kalyan has published most often in Oncotarget. Dr. Kalyan's most frequent co-authors are Francis J. Giles, MD, Riad Salem, MD and Laura M. Kulik, MD.

Dmand AI links Dr. Kalyan to 10 clinical trials, 4 of them phase 2 studies. 6 are still active or recruiting. Conditions studied include Pancreatic Neoplasms, Pancreatic Diseases and Anal Canal Carcinoma. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 133 general payments to Dr. Kalyan from 14 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 65% of the total. AstraZeneca Pharmaceuticals LP paid the most, $73,802. It also lists 2 research payments totaling $835 from 2016 to 2017.